Loading...
OTCM
NVYTF
Market cap36mUSD
Nov 03, Last price  
0.51USD
Name

Novacyt SA

Chart & Performance

D1W1MN
OTCM:NVYTF chart
P/E
P/S
1.38
EPS
Div Yield, %
Shrs. gr., 5y
9.08%
Rev. gr., 5y
11.93%
Revenues
20m
+69.53%
762,831901,9901,006,2313,539,1246,562,0139,441,22813,275,32112,369,30411,175,527277,204,00095,780,00021,040,00011,579,00019,630,000
Net income
-42m
L+47.60%
000000000132,423,000-9,728,000-22,201,000-28,292,000-41,758,000
CFO
-10m
L-60.69%
000000000102,976,00015,689,000-13,729,000-24,991,000-9,823,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
IPO date
Oct 12, 2012
Employees
222
Domiciled in
FR
Incorporated in
FR

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT